These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16213473)

  • 1. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography.
    Parsey RV; Kent JM; Oquendo MA; Richards MC; Pratap M; Cooper TB; Arango V; Mann JJ
    Biol Psychiatry; 2006 May; 59(9):821-8. PubMed ID: 16213473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.
    Voineskos AN; Wilson AA; Boovariwala A; Sagrati S; Houle S; Rusjan P; Sokolov S; Spencer EP; Ginovart N; Meyer JH
    Psychopharmacology (Berl); 2007 Sep; 193(4):539-45. PubMed ID: 17497139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB.
    Arakawa R; Tateno A; Kim W; Sakayori T; Ogawa K; Okubo Y
    Psychiatry Res Neuroimaging; 2016 May; 251():1-6. PubMed ID: 27082864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
    Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
    Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).
    Nogami T; Takano H; Arakawa R; Ichimiya T; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Takahata K; Suzuki M; Nagashima T; Mori T; Shimada H; Fukuda H; Sekine M; Tateno A; Takahashi H; Ito H; Okubo Y; Suhara T
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):937-43. PubMed ID: 23067569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
    Ginovart N; Wilson AA; Meyer JH; Hussey D; Houle S
    Synapse; 2003 Feb; 47(2):123-33. PubMed ID: 12454950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.
    Saijo T; Maeda J; Okauchi T; Maeda J; Morio Y; Kuwahara Y; Suzuki M; Goto N; Suzuki K; Higuchi M; Suhara T
    Int J Neuropsychopharmacol; 2009 Sep; 12(8):1021-32. PubMed ID: 19236731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.
    Smith GS; Kuwabara H; Gould NF; Nassery N; Savonenko A; Joo JH; Bigos KL; Kraut M; Brasic J; Holt DP; Hall AW; Mathews WB; Dannals RF; Nandi A; Workman CI
    Neuropharmacology; 2021 Aug; 194():108447. PubMed ID: 33450276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
    Stenkrona P; Halldin C; Lundberg J
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1190-8. PubMed ID: 23428337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging.
    Gryglewski G; Klöbl M; Berroterán-Infante N; Rischka L; Balber T; Vanicek T; Pichler V; Kautzky A; Klebermass EM; Reed MB; Vraka C; Hienert M; James GM; Silberbauer L; Godbersen GM; Unterholzner J; Michenthaler P; Hartenbach M; Winkler-Pjrek E; Wadsak W; Mitterhauser M; Hahn A; Hacker M; Kasper S; Lanzenberger R
    Eur Neuropsychopharmacol; 2019 Jun; 29(6):711-719. PubMed ID: 31076187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occupancy of serotonin transporter by tramadol: a positron emission tomography study with [11C]DASB.
    Ogawa K; Tateno A; Arakawa R; Sakayori T; Ikeda Y; Suzuki H; Okubo Y
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):845-50. PubMed ID: 24423243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
    Lundberg J; Tiger M; Landén M; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2012 Sep; 15(8):1167-72. PubMed ID: 22243688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-finding study of duloxetine based on serotonin transporter occupancy.
    Takano A; Suzuki K; Kosaka J; Ota M; Nozaki S; Ikoma Y; Tanada S; Suhara T
    Psychopharmacology (Berl); 2006 Apr; 185(3):395-9. PubMed ID: 16506079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls.
    Hinz R; Selvaraj S; Murthy NV; Bhagwagar Z; Taylor M; Cowen PJ; Grasby PM
    J Cereb Blood Flow Metab; 2008 Aug; 28(8):1478-90. PubMed ID: 18478022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DASB -in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer.
    Hummerich R; Reischl G; Ehrlichmann W; Machulla HJ; Heinz A; Schloss P
    J Neurochem; 2004 Sep; 90(5):1218-26. PubMed ID: 15312176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites.
    Zeng Z; Chen TB; Miller PJ; Dean D; Tang YS; Sur C; Williams DL
    Nucl Med Biol; 2006 May; 33(4):555-63. PubMed ID: 16720249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
    Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
    Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB.
    Bhagwagar Z; Murthy N; Selvaraj S; Hinz R; Taylor M; Fancy S; Grasby P; Cowen P
    Am J Psychiatry; 2007 Dec; 164(12):1858-65. PubMed ID: 18056241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.
    Frankle WG; Robertson B; Maier G; Paris J; Asmonga D; May M; Himes ML; Mason NS; Mathis CA; Narendran R
    Synapse; 2018 Mar; 72(3):. PubMed ID: 29216407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human 5-HT transporter availability predicts amygdala reactivity in vivo.
    Rhodes RA; Murthy NV; Dresner MA; Selvaraj S; Stavrakakis N; Babar S; Cowen PJ; Grasby PM
    J Neurosci; 2007 Aug; 27(34):9233-7. PubMed ID: 17715358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.